| Code | CSB-RA882153MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SAR-446523, targeting GPRC5D (G protein-coupled receptor class C group 5 member D). GPRC5D is an orphan G protein-coupled receptor predominantly expressed on plasma cells and malignant plasma cells in multiple myeloma, with minimal expression on normal tissues. This restricted expression pattern makes GPRC5D an attractive therapeutic target for hematological malignancies. The receptor plays a role in cellular signaling pathways, and its overexpression in multiple myeloma cells has been associated with disease progression and poor prognosis.
SAR-446523 (also known as talquetamab) is a bispecific T-cell engager antibody that redirects T cells to eliminate GPRC5D-expressing cells and has shown promising clinical activity in relapsed/refractory multiple myeloma. This biosimilar antibody provides researchers with a valuable tool for investigating GPRC5D biology, studying plasma cell differentiation, exploring novel immunotherapeutic mechanisms, and developing targeted approaches for multiple myeloma research. It supports preclinical studies aimed at understanding GPRC5D-mediated signaling and evaluating therapeutic strategies in oncology research.
There are currently no reviews for this product.